18,29 $
0,83 % vorgestern
Nasdaq, 16. Januar, 22:01 Uhr
ISIN
US38870X1046
Symbol
LENZ
Berichte

Graphite Bio Inc Aktie News

Neutral
GlobeNewsWire
4 Tage alt
Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours
Neutral
GlobeNewsWire
10 Tage alt
Launched VIZZ™  (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025
Neutral
GlobeNewsWire
13 Tage alt
SAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing & Consulting FZCO (“Lunatus”) today announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZTM for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commerci...
Positiv
Seeking Alpha
etwa ein Monat alt
LENZ Therapeutics, Inc. shares fell ~30% after a reported adverse event with VIZZ, but I do not view this as thesis-destroying. VIZZ offers superior efficacy and duration versus competitors, yet faces potentially slow market adoption and entrenched alternatives like glasses, contacts, and LASIK. LENZ's $3 billion market opportunity is plausible but hinges on shifting consumer behavior and overc...
Neutral
Seeking Alpha
etwa ein Monat alt
LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral
GlobeNewsWire
etwa 2 Monate alt
Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ
Neutral
GlobeNewsWire
etwa 2 Monate alt
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following...
Neutral
Seeking Alpha
2 Monate alt
LENZ Therapeutics, Inc. ( LENZ ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Daniel Chevallard - Chief Financial Officer Evert Schimmelpennink - President, CEO, Secretary & Director Shawn Olsson - Chief Commercial Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Biren Amin - Piper Sandle...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen